| Species |
Cynomolgus |
| Protein Construction |
GPC3/Glypican 3 (Gln25-His559)
Accession # XP_005594665.1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized GPC3/Glypican 3, His, Cynomolgus at 1μg/ml (100μl/well) on the plate can bind AntiGPC3 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
61.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 42 kDa, 70-135 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Glypican-3 is a protein ,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed. |
| Synonyms |
GPC3; DGSX; Glypican 3; GTR2-2; MXR7; OCI5; OCI-5; SGB; SGBS; SGBS1SDYS; SDYS; SGBS1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
